United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund Makes New $242,000 Investment in DaVita Inc. $DVA

United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund purchased a new stake in DaVita Inc. (NYSE:DVA) during the second quarter, according to its most recent 13F filing with the SEC. The firm purchased 1,700 shares of the company’s stock, valued at approximately $242,000.

Several other large investors have also recently modified their holdings of the company. Invesco Ltd. boosted its stake in DaVita by 3.4% in the first quarter. Invesco Ltd. now owns 1,642,947 shares of the company’s stock valued at $251,322,000 after acquiring an additional 53,402 shares in the last quarter. Northern Trust Corp raised its position in shares of DaVita by 20.2% in the 1st quarter. Northern Trust Corp now owns 890,632 shares of the company’s stock valued at $136,240,000 after purchasing an additional 149,858 shares during the last quarter. Gates Capital Management Inc. increased its stake in DaVita by 0.7% during the 1st quarter. Gates Capital Management Inc. now owns 722,205 shares of the company’s stock valued at $110,476,000 after purchasing an additional 4,698 shares in the last quarter. Amundi raised its holdings in shares of DaVita by 16.0% in the first quarter. Amundi now owns 517,690 shares of the company’s stock worth $79,584,000 after buying an additional 71,304 shares during the last quarter. Finally, Epoch Investment Partners Inc. lifted its stake in shares of DaVita by 10.7% during the first quarter. Epoch Investment Partners Inc. now owns 407,921 shares of the company’s stock worth $62,400,000 after buying an additional 39,485 shares during the period. Institutional investors own 90.12% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the company. Bank of America reduced their target price on DaVita from $145.00 to $140.00 and set an “underperform” rating for the company in a research note on Wednesday, September 10th. Wall Street Zen downgraded DaVita from a “buy” rating to a “hold” rating in a report on Saturday, October 11th. TD Cowen decreased their price objective on shares of DaVita from $154.00 to $133.00 and set a “hold” rating for the company in a research note on Monday, November 3rd. Zacks Research cut shares of DaVita from a “hold” rating to a “strong sell” rating in a report on Thursday, October 30th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of DaVita in a report on Tuesday. Five equities research analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Reduce” and an average price target of $148.00.

DaVita Stock Down 0.9%

Shares of DVA opened at $120.22 on Friday. The company has a market capitalization of $8.49 billion, a PE ratio of 12.38, a price-to-earnings-growth ratio of 0.91 and a beta of 1.13. The stock has a fifty day simple moving average of $125.22 and a two-hundred day simple moving average of $133.93. DaVita Inc. has a 52-week low of $113.97 and a 52-week high of $179.60.

DaVita (NYSE:DVA) last released its quarterly earnings results on Wednesday, October 29th. The company reported $2.51 EPS for the quarter, missing the consensus estimate of $3.17 by ($0.66). The firm had revenue of $3.42 billion for the quarter, compared to analysts’ expectations of $3.43 billion. DaVita had a net margin of 5.80% and a return on equity of 815.62%. The firm’s quarterly revenue was up 4.8% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.59 EPS. DaVita has set its FY 2025 guidance at 10.350-11.150 EPS. As a group, equities analysts anticipate that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.